Last updated on March 2020

First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD

Brief description of study

This is an open label first in human Phase 1/2 multicentre study of GT005 in subjects with Macular Atrophy due to AMD

Detailed Study Description

This study will evaluate the safety, the dose response and efficacy (anatomical and functional visual outcomes) of two doses of GT005 administered as a single subretinal injection in genetically defined subjects with Macular Atrophy due to Age-related Macular Degeneration (AMD). Following consent, subjects will undergo a number of ophthalmic and clinical assessments to determine eligibility for inclusion in the study. Once eligibility is confirmed, subjects will be enrolled, receive treatment, and will be followed for 48 weeks.

Clinical Study Identifier: NCT03846193

Find a site near you

Start Over

Bristol Eye Hospital

Bristol, United Kingdom
  Connect »

Manchester Eye Hospital

Manchester, United Kingdom
  Connect »

Southampton General Hospital

Southampton, United Kingdom
  Connect »

Sunderland Eye Infirmary

Sunderland, United Kingdom
  Connect »